Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Review

CHD1L: a novel oncogene

Authors: Wen Cheng, Yun Su, Feng Xu

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer and ~ 140 driver genes have been identified, but not all of them have been extensively investigated. CHD1L (chromodomain helicase/ATPase DNA binding protein 1-like gene) or ALC1 (amplified in liver cancer 1) is a newly identified oncogene located at Chr1q21 and it is amplified in many solid tumors. Functional studies of CHD1L in hepatocellular carcinoma and other tumors strongly suggested that its oncogenic role in tumorigenesis is through unleashed cell proliferation, G1/S transition and inhibition of apoptosis. The underlying mechanisms of CHD1L activation may disrupt the cell death program via binding the apoptotic protein Nur77 or through activation of the AKT pathway by up-regulation of CHD1L-mediated target genes (e.g., ARHGEF9, SPOCK1 or TCTP). CHD1L is now considered to be a novel independent biomarker for progression, prognosis and survival in several solid tumors. The accumulated knowledge about its functions will provide a focus to search for targeted treatment in specific subtypes of tumors.
Appendix
Available only for authorised users
Literature
1.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW: Cancer genome landscapes. Science. 2013, 339: 1546-1558. 10.1126/science.1235122PubMedCentralCrossRefPubMed
2.
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature. 1999, 400: 464-468. 10.1038/22780CrossRefPubMed
3.
Wu W, Chan JA: Understanding the Role of Long Noncoding RNAs in the Cancer Genome. Next Generation Sequencing in Cancer Research-Decoding Cancer Genome. Volume Vol 1. Edited by: Wu W, Choudhry H. 2013, 199-215. New York: Springer, 1CrossRef
4.
Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011, 144: 27-40. 10.1016/j.cell.2010.11.055PubMedCentralCrossRefPubMed
5.
Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ: Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol. 1998, 185: 345-351. 10.1002/(SICI)1096-9896(199808)185:4<345::AID-PATH109>3.0.CO;2-0CrossRefPubMed
6.
Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP: Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer. 1998, 21: 177-184. 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.0.CO;2-XCrossRefPubMed
7.
Fang Y, Guan X, Guo Y, Sham J, Deng M, Liang Q, Li H, Zhang H, Zhou H, Trent J: Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer. 2001, 30: 254-260. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1086>3.0.CO;2-DCrossRefPubMed
8.
Guan XY, Fang Y, Sham J, Kwong D, Zhang Y, Liang Q, Li H, Zhou H, Trent J: Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2001, 30: 110- 10.1002/1098-2264(2000)9999:9999<::AID-GCC1063>3.0.CO;2-OCrossRefPubMed
9.
Kwong D, Lam A, Guan X, Law S, Tai A, Wong J, Sham J: Chromosomal aberrations in esophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor prognosis after surgery. Hum Pathol. 2004, 35: 309-316. 10.1016/j.humpath.2003.10.020CrossRefPubMed
10.
Niini T, Lopez-Guerrero JA, Ninomiya S, Guled M, Hattinger CM, Michelacci F, Bohling T, Llombart-Bosch A, Picci P, Serra M, Knuutila S: Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone–an array comparative genomic hybridization study. Genes Chromosomes Cancer. 2010, 49: 132-143.PubMed
11.
Ji X, Li J, Zhu L, Cai J, Zhang J, Qu Y, Zhang H, Liu B, Zhao R, Zhu Z: CHD1L promotes tumor progression and predicts survival in colorectal carcinoma. J Surg Res. 2013, 185 (1): 84-91. 10.1016/j.jss.2013.05.008CrossRefPubMed
12.
Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen L, Tang DJ, Fu L, Wu Z, Chen M: Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology. 2008, 47: 503-510.CrossRefPubMed
13.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG: The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012, 22: 1775-1789. 10.1101/gr.132159.111PubMedCentralCrossRefPubMed
14.
Brockschmidt A, Chung B, Weber S, Fischer DC, Kolatsi-Joannou M, Christ L, Heimbach A, Shtiza D, Klaus G, Simonetti GD: CHD1L: a new candidate gene for congenital anomalies of the kidneys and urinary tract (CAKUT). Nephrol Dial Transplant. 2012, 27: 2355-2364. 10.1093/ndt/gfr649CrossRefPubMed
15.
Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA. 2004, 101: 6062-6067. 10.1073/pnas.0400782101PubMedCentralCrossRefPubMed
16.
17.
Karras GI, Kustatscher G, Buhecha HR, Allen MD, Pugieux C, Sait F, Bycroft M, Ladurner AG: The macro domain is an ADP-ribose binding module. EMBO J. 2005, 24: 1911-1920. 10.1038/sj.emboj.7600664PubMedCentralCrossRefPubMed
18.
Ahel D, Horejsi Z, Wiechens N, Polo SE, Garcia-Wilson E, Ahel I, Flynn H, Skehel M, West SC, Jackson SP: Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science. 2009, 325: 1240-1243. 10.1126/science.1177321PubMedCentralCrossRefPubMed
19.
Gottschalk AJ, Timinszky G, Kong SE, Jin J, Cai Y, Swanson SK, Washburn MP, Florens L, Ladurner AG, Conaway JW, Conaway RC: Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc Natl Acad Sci USA. 2009, 106: 13770-13774. 10.1073/pnas.0906920106PubMedCentralCrossRefPubMed
20.
Gottschalk AJ, Trivedi RD, Conaway JW, Conaway RC: Activation of the SNF2 family ATPase ALC1 by poly(ADP-ribose) in a stable ALC1.PARP1.nucleosome intermediate. J Biol Chem. 2012, 287: 43527-43532. 10.1074/jbc.M112.401141PubMedCentralCrossRefPubMed
21.
Chen L, Hu L, Chan TH, Tsao GS, Xie D, Huo KK, Fu L, Ma S, Zheng BJ, Guan XY: Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival. Hepatology. 2009, 50: 122-129. 10.1002/hep.22933CrossRefPubMed
22.
Snider AC, Leong D, Wang QT, Wysocka J, Yao MW, Scott MP: The chromatin remodeling factor Chd1l is required in the preimplantation embryo. Biol Open. 2013, 2: 121-131. 10.1242/bio.20122949PubMedCentralCrossRefPubMed
23.
Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S, Wang J, Dong SS, Tang KH, Xie D: CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 2010, 120: 1178-1191. 10.1172/JCI40665PubMedCentralCrossRefPubMed
24.
Chan TH, Chen L, Liu M, Hu L, Zheng BJ, Poon VK, Huang P, Yuan YF, Huang JD, Yang J: Translationally controlled tumor protein induces mitotic defects and chromosome missegregation in hepatocellular carcinoma development. Hepatology. 2012, 55: 491-505. 10.1002/hep.24709CrossRefPubMed
25.
Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL, Li Y, Yuan YF, Guan XY: SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology. 2013, 144: 179-191. e174, 10.1053/j.gastro.2012.09.042CrossRefPubMed
26.
Eriksson P, Aine M, Sjodahl G, Staaf J, Lindgren D, Hoglund M: Detailed analysis of focal chromosome Arm 1q and 6p amplifications in urothelial carcinoma reveals complex genomic events on 1q, and as a possible auxiliary target on 6p. PLoS One. 2013, 8: e67222- 10.1371/journal.pone.0067222PubMedCentralCrossRefPubMed
27.
Chen M, Huang JD, Hu L, Zheng BJ, Chen L, Tsang SL, Guan XY: Transgenic CHD1L expression in mouse induces spontaneous tumors. PLoS One. 2009, 4: e6727- 10.1371/journal.pone.0006727PubMedCentralCrossRefPubMed
28.
Prokopczyk B, Sinha I, Trushin N, Freeman WM, El-Bayoumy K: Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Chem Biol Interact. 2009, 177: 173-180. 10.1016/j.cbi.2008.10.051PubMedCentralCrossRefPubMed
29.
Hyeon J, Ahn S, Park CK: CHD1L Is a marker for poor prognosis of hepatocellular carcinoma after surgical resection. Korean J Pathol. 2013, 47: 9-15. 10.4132/KoreanJPathol.2013.47.1.9PubMedCentralCrossRefPubMed
30.
He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, Guan XY, Xie D, Yang GF: CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. BMC Cancer. 2012, 12: 437- 10.1186/1471-2407-12-437PubMedCentralCrossRefPubMed
31.
Tian F, Xu F, Zhang ZY, Ge JP, Wei ZF, Xu XF, Cheng W: Expression of CHD1L in bladder cancer and its influence on prognosis and survival. Tumour Biol. 2013, 34 (6): 3687-90. 10.1007/s13277-013-0951-4CrossRefPubMed
32.
Chen L, Yuan YF, Li Y, Chan TH, Zheng BJ, Huang J, Guan XY: Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. Gut. 2011, 60: 534-543. 10.1136/gut.2010.224071CrossRefPubMed
33.
Burnett JC, Rossi JJ, Tiemann K: Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011, 6: 1130-1146. 10.1002/biot.201100054PubMedCentralCrossRefPubMed
34.
Han W, Li X, Fu X: The macro domain protein family: structure, functions, and their potential therapeutic implications. Mutat Res. 2011, 727: 86-103. 10.1016/j.mrrev.2011.03.001CrossRefPubMed
Metadata
Title
CHD1L: a novel oncogene
Authors
Wen Cheng
Yun Su
Feng Xu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-170

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion

Research

DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survival

Research

Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary

Research

Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type

Research

BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification

Research

Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits